Founded in 1875 and headquartered in Indianapolis, Eli Lilly has grown into a trillion-dollar pharma giant posting $65.2B in FY2025 revenue.
Eli Lilly & Co is one of America's oldest and largest pharmaceutical companies. Founded in 1875 and headquartered in Indianapolis, Indiana, it has grown over 150 years from a regional drug manufacturer into a trillion-dollar enterprise. The company trades on the New York Stock Exchange under the ticker LLY, with a recent share price of $1,208.12 — near its 52-week high.
**What the Company Makes**
Lilly focuses its efforts on four therapeutic areas: neuroscience, cardiometabolic conditions, cancer, and immunology. Its cancer portfolio includes Verzenio and Jaypirca. The cardiometabolic lineup — which has drawn wide attention in recent years — includes Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin. For immunology, Lilly markets Taltz and Olumiant. This breadth across major disease categories reflects decades of research investment and a deliberate strategy to compete in multiple high-value markets at once.
**Revenue and Profitability**
Lilly reported $65.2 billion in revenue for fiscal year 2025. To put that figure in context, revenue grew 130% between FY2021 and FY2025 — more than doubling in four years. Growth at that pace is unusual for an established pharmaceutical company and points to strong commercial momentum across its product lines.
Net income for FY2025 was $20.6 billion, translating to a net margin of 31.7%. In plain terms, Lilly kept roughly 32 cents of profit for every dollar of sales. The gross margin of 83.0% reflects a defining characteristic of the pharmaceutical business: once a drug clears development and regulatory hurdles, the cost of producing and distributing it is relatively low compared to what it commands in the market. Total assets stand at $112.5 billion.
**Market Valuation**
A market capitalization of $1.0 trillion means the combined market value of all outstanding Lilly shares equals one trillion dollars — a threshold very few American companies have ever crossed. That figure reflects not only current earnings but investor expectations about future growth.
The stock carries a price-to-earnings ratio of 52.6. P/E ratios compare a company's share price to its per-share earnings; a higher ratio generally signals that investors expect earnings to grow substantially. The broader U.S. stock market has historically traded at a P/E in the low-to-mid twenties, so Lilly's ratio indicates that the market is pricing in continued expansion well above the corporate average.
**Dividends and Workforce**
Lilly pays shareholders a dividend with an annual yield of approximately 0.57%. That is a modest payout relative to its share price, which is typical for companies channeling significant resources back into research and development. The company employs approximately 50,000 people across its manufacturing, research, commercial, and administrative operations.
**A Long Record, a Recent Surge**
Lilly went public in July 1970, but its roots stretch back to 1875. The company has navigated more than a century of shifting science, regulation, and competition. The 130% revenue growth recorded between FY2021 and FY2025 stands out as one of the more striking stretches in its modern history. With $65.2 billion in revenue, $20.6 billion in net income, and a trillion-dollar market cap, Eli Lilly sits at the top tier of American pharmaceutical companies by nearly every financial measure.
This article is factual reporting drawn from public filings and market data, and is not investment advice.